Justification of disintegration testing beyond current FDA criteria using in vitro and in silico models
Lukas Uebbing,1,2,* Lukas Klumpp,1,3,* Gregory K Webster,4 Raimar Löbenberg1 1Faculty of Pharmacy and Pharmaceutical Sciences, Katz Group-Rexall Centre for Pharmacy and Health Research, University of Alberta, Edmonton, Canada; 2Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, M...
Saved in:
Main Authors: | Uebbing L (Author), Klumpp L (Author), Webster GK (Author), Löbenberg R (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2017-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An overview on FDA-approved natural super disintegrants efficacy in a fast dissolving drug delivery system
by: Darshan Pradhan, et al.
Published: (2021) -
Formulation and in vitro Evaluations of Paracetamol Orally Disintegrating Tablets
by: Azmiera Azimuddin, et al.
Published: (2023) -
The Consistency of Panoramic Radiography Selection Criteria by Dentists in Tehran with the FDA Guidelines
by: Sima Nikneshan, et al.
Published: (2013) -
In Vitro Dissolution and in Silico Modeling Shortcuts in Bioequivalence Testing
by: Moawia M. Al-Tabakha, et al.
Published: (2020) -
Justification of early neurorehabilitation in neonates
by: L.P. Badogina, et al.
Published: (2017)